Inhibikase Therapeutics, Inc. (IKT)
Market Cap | 16.87M |
Revenue (ttm) | 61,818 |
Net Income (ttm) | -18.82M |
Shares Out | 28.03M |
EPS (ttm) | -0.74 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 175,813 |
Open | 0.602 |
Previous Close | 0.600 |
Day's Range | 0.602 - 0.644 |
52-Week Range | 0.440 - 1.520 |
Beta | 0.97 |
Analysts | Sell |
Price Target | 6.12 (+916.61%) |
Earnings Date | Mar 30, 2023 |
About IKT
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib th... [Read more]
Financial Performance
In 2021, IKT's revenue was $3.10 million, an increase of 343.92% compared to the previous year's $698,468. Losses were -$14.79 million, 419.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for IKT stock is "Sell." The 12-month stock price forecast is $6.12, which is an increase of 916.61% from the latest price.
News

Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders
BOSTON and ATLANTA , March 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor...

Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023
BOSTON and ATLANTA , March 16, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor...

Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro
Completed dosing of 3 of 4 planned cohorts; expect to complete study in the second quarter of 2023 BOSTON and ATLANTA , March 15, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inh...

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy
- Advancing model studies of IkT-148009 in MSA; early data has shown a substantial neuroprotective benefit in response to c-Abl inhibition by IkT-148009 – - MSA IND Opened, the 5th in the Company's hi...

Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
BOSTON and ATLANTA , Feb. 15, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules
BOSTON and ATLANTA , Jan. 27, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today?
Inhibikase Therapeutics (NASDAQ: IKT) stock is falling on Thursday after the company announced a registered direct offering and private placement. Starting with the registered direct offering up 6,74...

Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules
BOSTON and ATLANTA , Jan. 25, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders
- Animal model studies highlight potential of the c-Abl inhibitor IkT-148009 to modify the course of Parkinson's Disease and Suppress Protein Pathology - BOSTON and ATLANTA , Jan. 25, 2023 /PRNewswire...

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease
- Phase 2a '201' clinical trial will resume immediately at 50 and 100 mg doses- -Additional safety and pharmacokinetic information will be measured in healthy subjects at the 200 mg dose prior to impl...

Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro
BOSTON and ATLANTA , Dec. 12, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs
BOSTON and ATLANTA , Dec. 7, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or the "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibit...

Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
BOSTON and ATLANTA, Nov. 22, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to ...

Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
Company to host conference call and webcast on November 15, 2022 at 8:00am ET BOSTON and ATLANTA , Nov. 14, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company")...

Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
BOSTON and ATLANTA , Nov. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor t...

Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs
BOSTON and ATLANTA , Nov. 7, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor t...

Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference
BOSTON and ATLANTA , Oct. 12, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to...

Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference
BOSTON and ATLANTA , Sept. 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics t...

Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress
IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system (CNS) in older and elderly healthy volunteers and Parkinson's patients No clinicall...

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
BOSTON and ATLANTA , Sept. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to...

Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors
BOSTON and ATLANTA , Sept. 1, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Par...

Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
BOSTON and ATLANTA, Aug. 26, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to ...

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
BOSTON and ATLANTA , Aug. 23, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Par...

Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
Company to host conference call and webcast on Monday, August 15, 2022, at 8:00am ET BOSTON and ATLANTA , Aug. 12, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Co...

Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022
BOSTON and ATLANTA , Aug. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Park...